The biopharma world kicks off each year with a frenzy of activity at JP Morgan. Endpoints has been there to chronicle it with wall-to-wall coverage, and our founder and editor John Carroll has convened top newsmakers to provide detailed insights about their strategies. For #JPM22, Endpoints is expanding on our proud tradition with multiple panels addressing the most important issues in biopharma R&D.
Can the new checkpoint inhibitors in the clinic change the landscape of cancer care? Or is this just a new wave of frustration? By the end of Q1, we’re likely to see the first approval of a new checkpoint inhibitor since PD-(L)1 permanently altered the landscape of cancer therapy. But can LAG-3, or TIGIT, etc., have a significant impact in expanding the effectiveness of PD-(L)1? Hope is mixed with considerable skepticism, and we’ll map out the debate in an in-depth report.
Can the new checkpoint inhibitors in the clinic change the landscape of cancer care? Or is this just a new wave of frustration? By the end of Q1, we’re likely to see the first approval of a new checkpoint inhibitor since PD-(L)1 permanently altered the landscape of cancer therapy. But can LAG-3, or TIGIT, etc., have a significant impact in expanding the effectiveness of PD-(L)1? Hope is mixed with considerable skepticism, and we’ll map out the debate in an in-depth report.
Endpoints News and Chris Dokomajilar at DealForma are back with our annual breakdown of the top 100 VCs in biotech — a field that has undergone some dramatic changes in the past 5 years. Who’s a player? Who’s on the sidelines looking to jump in? Endpoints founder John Carroll will also host a webinar looking at a fascinating piece of the funding scene in the industry.
Endpoints News and Chris Dokomajilar at DealForma are back with our annual breakdown of the top 100 VCs in biotech — a field that has undergone some dramatic changes in the past 5 years. Who’s a player? Who’s on the sidelines looking to jump in? Endpoints founder John Carroll will host a webinar looking at a fascinating piece of the funding scene in the industry.
A list of drugs in development with the biggest launch potential
A list of 10 high-profile mistakes in the industry, examined and analyzed
Now that some of the first AI-inspired drugs are in the clinic, what do they tell us about a field that has attracted billions of dollars in investment based on equal parts of scientific calculation and hype? We will tackle this question with a panel of experts during this crucial time for the booming field, as investigators begin to gather the first hard human data that will either drive fresh efforts, or cloud all their efforts.
Now that some of the first AI-inspired drugs are in the clinic, what do they tell us about a field that has attracted billions of dollars in investment based on equal parts of scientific calculation and hype? We will tackle this question with a panel of experts during this crucial time for the booming field, as investigators begin to gather the first hard human data that will either drive fresh efforts, or cloud all their efforts.
Exclusive insights from a group of hand-picked biotech CEOs and A-list investors, and more
Recent human data has helped encourage a new brand of biotech out to use modified psychedelics to rewire the brain in search of new and better therapies for mental health. Once a marginalized, if not simply criminalized, research field, these new companies are luring investors and inspiring a range of new clinical programs. And J&J has helped drive the work with a pioneering — and still highly controversial — drug approval for esketamine that has both created new regulatory precedents while spurring debate about the future of the field.
Recent human data has helped encourage a new brand of biotech out to use modified psychedelics to rewire the brain in search of new and better therapies for mental health. Once a marginalized, if not simply criminalized, research field, these new companies are luring investors and inspiring a range of new clinical programs. And J&J has helped drive the work with a pioneering — and still highly controversial — drug approval for esketamine that has both created new regulatory precedents while spurring debate about the future of the field.
Once again Endpoints News founder John Carroll will dissect how the top 15 R&D organizations in the world — ranked by research spends — are doing. Over the past 10 years there have been some major changes in these groups, as R&D chiefs evaluate where to get the biggest bang for their buck. What are the big challenges in 2022 for the top R&D chiefs? And who’s winning, or losing, the multibillion-dollar battle on ROI.
Once again Endpoints News founder John Carroll will dissect how the top 15 R&D organizations in the world — ranked by research spends — are doing. Over the past 10 years there have been some major changes in these groups, as R&D chiefs evaluate where to get the biggest bang for their buck. What are the big challenges in 2022 for the top R&D chiefs? And who’s winning, or losing, the multibillion-dollar battle on ROI.
In recent years we’ve seen biomarkers like ctDNA change the course of cancer studies, offering a shortcut to the market while offering a much clearer picture of what patient subgroups are likely to benefit from the slew of experimental therapies in the clinic. What new biomarkers are being hatched today? And what impact will they have in a field that has already seen development timelines shift dramatically?
In recent years we’ve seen biomarkers like ctDNA change the course of cancer studies, offering a shortcut to the market while offering a much clearer picture of what patient subgroups are likely to benefit from the slew of experimental therapies in the clinic. What new biomarkers are being hatched today? And what impact will they have in a field that has already seen development timelines shift dramatically?
Some security firms have warned that biopharma companies are increasingly being targeted for cyberattacks (Merck is still dealing with the aftermath of the 2017 attack). How vulnerable are drug developers, what's at stake and what steps are being taken / can be taken / to prevent a devastating attack? And what are the best strategies for both big and small organizations.
Some security firms have warned that biopharma companies are increasingly being targeted for cyberattacks (Merck is still dealing with the aftermath of the 2017 attack). How vulnerable are drug developers, what's at stake and what steps are being taken / can be taken / to prevent a devastating attack? And what are the best strategies for both big and small organizations.
A list of 10 high-profile mistakes in the industry, examined and analyzed
Plenty of pain to go around, but who’s making gains? The pipeline for new pain drugs has grown perilously thin in recent years with a slate of key clinical trial failures. Only a few small players are still actively engaged in developing new therapies to replace the aging therapeutics that now dominate the market, especially after Pfizer’s last setback on an anti-NGF drug, finally closing that chapter of new drug development. Endpoints News will take a close look at the conditions that are limiting access to new drugs and the intense medical need to find drugs that can do a better job for an aging population. Lei Lei Wu will dig in to explain what’s happening here.
Plenty of pain to go around, but who’s making gains? The pipeline for new pain drugs has grown perilously thin in recent years with a slate of key clinical trial failures. Only a few small players are still actively engaged in developing new therapies to replace the aging therapeutics that now dominate the market, especially after Pfizer’s last setback on an anti-NGF drug, finally closing that chapter of new drug development. Endpoints news will take a close look at the conditions that are limiting access to new drugs and the intense medical need to find drugs that can do a better job for an aging population. Lei Lei Wu will dig in to explain what’s happening here.
Have we finally reached a turning point? The headlines haven’t been encouraging when it comes to Parkinson’s, one of the toughest targets in R&D. AbbVie broke off a deal on alpha-synuclein as a target. One of the gene therapy efforts has foundered. There are a slate of GLP-1 and gene therapy programs in the clinic, but what realistically are their chances? Anyone who can make a significant advance, though, stands to gain access to one of the largest markets in medicine. What are the leading scientists saying about the road ahead?
Have we finally reached a turning point? The headlines haven’t been encouraging when it comes to Parkinson’s, one of the toughest targets in R&D. AbbVie broke off a deal on alpha-synuclein as a target. One of the gene therapy efforts has foundered. There are a slate of GLP-1 and gene therapy programs in the clinic, but what realistically are their chances? Anyone who can make a significant advance, though, stands to gain access to one of the largest markets in medicine. What are the leading scientists saying about the road ahead?
The Endpoints team will be covering all the major developments at this annual event. We’ll be matching the special report we do on the Monday of the science conference with a fireside chat and wrap it up with a panel of experts reviewing the most important data.
The Endpoints team will be covering all the major developments at this annual event. We’ll be matching the special report we do on the Monday of the science conference with a fireside chat and wrap it up with a panel of experts reviewing the most important data.
Exclusive insights from a group of hand-picked biotech CEOs and A-list investors, and more
A host of issues have clouded patient recruitment for clinical trials, causing some severe issues for drug developers. Patient access to drug studies -- particularly in oncology -- has been a growing problem, along with key challenges in hiring site staff and the limitations involved with the structures now in place for managing trials. Endpoints News’ Kyle LaHucik has been digging deep into this, and offers a detailed look at the problems and potential solutions
A host of issues have clouded patient recruitment for clinical trials, causing some severe issues for drug developers. Patient access to drug studies -- particularly in oncology -- has been a growing problem, along with key challenges in hiring site staff and the limitations involved with the structures now in place for managing trials. Endpoints News’ Kyle LaHucik has been digging deep into this, and offers a detailed look at the problems and potential solutions
Endpoints News will feature a prominent group of the top executives leading a new generation of European biotechs in an industry that has undergone major changes in recent years
The pandemic changed everything in vaccine development, and now the whole world is catching up. Endpoints News senior editor Amber Tong will cover the new world of vaccine research as officials look to vaccinate against viral threats like monkeypox and the Covid variants on timelines that would have been considered impossible just 2 years ago. Tong will also cover the deep changes that are transforming vaccine manufacturing and delivery as governments prime the vaccine R&D pump with billions to support a revolution in fast development. Millions of lives are on the line as viruses now spread faster than ever.
The pandemic changed everything in vaccine development, and now the whole world is catching up. Endpoints News senior editor Amber Tong will cover the new world of vaccine research as officials look to vaccinate against viral threats like monkeypox and the Covid variants on timelines that would have been considered impossible just 2 years ago. Tong will also cover the deep changes that are transforming vaccine manufacturing and delivery as governments prime the vaccine R&D pump with billions to support a revolution in fast development. Millions of lives are on the line as viruses now spread faster than ever.
The news that a prominent insurer had decided to cover a digital therapeutic for opioid disorder spurred national headlines recently. In this case, the therapeutic had a breakthrough designation from the FDA. That payer decision underscored the potential as well as the challenges that have arisen around developing and marketing digital therapeutics, which have become a fast-growing segment within digital healthcare. DTx delivers clinical interventions directly to patients via software to treat, manage or prevent disease — ranging from behavioral health conditions to diabetes. We’ll take a close look at this burgeoning field and see where we’re headed in the years to come.
The news that a prominent insurer had decided to cover a digital therapeutic for opioid disorder spurred national headlines recently. In this case, the therapeutic had a breakthrough designation from the FDA. That payer decision underscored the potential as well as the challenges that have arisen around developing and marketing digital therapeutics, which have become a fast-growing segment within digital healthcare. DTx delivers clinical interventions directly to patients via software to treat, manage or prevent disease — ranging from behavioral health conditions to diabetes. We’ll take a close look at this burgeoning field and see where we’re headed in the years to come.
Endpoints News reports on all the top news out of the world’s premier cell and gene therapy science conference. We will convene an online panel discussion on what topics grabbed the attention of the experts.